You are here

Article Text

Article menu
Download PDFPDF
Letter
Gout in liver transplant patients receiving tacrolimus
  1. J C Gerster1,
  2. M Dudler1,
  3. N Halkic2,
  4. M Gillet2
  1. 1Department of Rheumatology, University Hospital (CHUV), Lausanne, Switzerland
  2. 2Department of Surgery, University Hospital (CHUV), Lausanne, Switzerland
  1. Correspondence to:
    Professeur J C Gerster
    Service de Rhumatologie, CHUV, 1011 Lausanne, Switzerland; Jean-Charles.Gersterchuv.hospvd.ch

https://doi.org/10.1136/ard.2003.006478

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Hyperuricaemia and gout have been reported in organ transplant patients treated with cyclosporin, an immunosuppressant inhibiting calcineurin.1,2 Tacrolimus, another calcineurin inhibitor, is nowadays widely used in place of cyclosporin. Hyperuricaemia has been seen in patients receiving tacrolimus3 but, to our knowledge, only rare cases of gout have been mentioned so far.4

    Since 1998, 31 patients (22 men, 9 women; current mean age 53 years (range 24–67)) have regularly received tacrolimus for immunosuppression after liver transplantation in the surgical department of Lausanne University Hospital. The mean duration of follow up with tacrolimus treatment was 27.8 months (range 7–57).

    In two cases the first manifestations of gout appeared after liver transplantation when these two patients were receiving tacrolimus for immunosuppression.

    CASE REPORTS

    Patient 1

    A 31 year old man received a liver transplant in November 1998. He was treated …

    View Full Text